Answers are grounded in this paper and cite their sources.
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a retrospective analysis of 104 HTx recipients with diabetes (23 exposed to SGLT2i, 81 not exposed), SGLT2i treatment was associated with stable renal function at 3 years post-HTx, measured by estimated glomerular filtration rate change from baseline (median change of 0 ml/min/1.73 m 2 (interquartile range [IQR] −13 to +11)), compared to a change of −15 ml/min/1.73 m 2 (IQR −27 to +1) in patients not exposed to SGLT2i ( p = 0.02). There was no significant difference in survival by SGLT2i exposure, adjusted for diabetes type and baseline creatinine (hazard ratio 0.34, confidence intervals 0.11-1.06, p = 0.06). Further investigation of SGLT2i in HTx recipients, particularly focusing on renal outcomes, is required.
No takes yet. Share an insight, caveat, or question.
Raven et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: